Overview
Venture capital firm investing in innovative startups.
Founded
2021
Deals · 12mo
5
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
CORE Biomedicine | Jul 2026Led | $21 MSeries A | |
Oricell Therapeutics | Apr 2026Participated | $110 MOther Equity | |
Angitia Biopharmaceuticals | Feb 2026Participated | $130 MSeries D | |
Fortitude Biomedicines | Jan 2026Led | $13 MSeed | |
Oricell Therapeutics | Jan 2026Participated | $70 MSeries C | |
Angitia Biopharmaceuticals | Dec 2024Participated | $120 MSeries C | |
Angitia Biopharmaceuticals | Oct 2023Participated | $46 MSeries B | |
Innovac Therapeutics | Sep 2023Participated | $18 MSeries A | |
Eccogene | Jun 2023Participated | $25 MSeries B | |
Allorion Therapeutics | Mar 2023Participated | $50 MSeries B | |
Ucello Therapeutics | Feb 2022Participated | $25 MSeries A | |
Allorion Therapeutics | Nov 2021Participated | $40 MSeries A | |
CORE Biomedicine | Jul 2026Led | $21 MSeries A | |
Oricell Therapeutics | Apr 2026Participated | $110 MOther Equity | |
Angitia Biopharmaceuticals | Feb 2026Participated | $130 MSeries D | |
Fortitude Biomedicines | Jan 2026Led | $13 MSeed | |
Oricell Therapeutics | Jan 2026Participated | $70 MSeries C | |
Angitia Biopharmaceuticals | Dec 2024Participated | $120 MSeries C | |
Angitia Biopharmaceuticals | Oct 2023Participated | $46 MSeries B | |
Innovac Therapeutics | Sep 2023Participated | $18 MSeries A | |
Eccogene | Jun 2023Participated | $25 MSeries B | |
Allorion Therapeutics | Mar 2023Participated | $50 MSeries B | |
Ucello Therapeutics | Feb 2022Participated | $25 MSeries A | |
Allorion Therapeutics | Nov 2021Participated | $40 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 1 | 3 |
| Series B | 0 | 3 |
| Series C+ | 0 | 3 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 1 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 2 |
| Feb '26 | 1 |
| Mar '26 | 0 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 1 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 12 |
| Consumer & Lifestyle | 3 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 3 |
| $25M-$50M | 4 |
| $50M-$100M | 2 |
| $100M-$250M | 3 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| China | 7 |
| United States | 5 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Qiming Venture Partners | 4 |
| 3H Health Investment | 3 |
| Legend Capital | 3 |
| OrbiMed | 3 |
| TF Capital | 3 |
| Bain Capital Life Sciences | 2 |
| Beijing Pharmaceutical and Health Industry Investment Fund | 2 |
| Janus Henderson Investors | 2 |
| NGS Super | 2 |
| Octagon Capital | 2 |
| Talon Capital | 2 |
| Yonghua Capital | 2 |
| 3SBio | 1 |
| Ascenta Capital | 1 |
| BlackRock | 1 |
| BVF Partners | 1 |
| Chengdu Bio-town Fund | 1 |
| Co-win Ventures | 1 |
| Delos Capital | 1 |
| Everjoy Fortune | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 2 | 17% |
| Participating | 10 | 83% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 2 | 100% |